Between our winner and these first two runners-up, we can safely say that it's been a big couple of weeks in the patent world. 

First up, a team of heavy hitters representing Qualcomm scored a huge win at the Ninth Circuit on August 11 that vacated U.S. District Judge Lucy Koh's judgment in favor of the Federal Trade Commission in its antitrust case targeting the company's licensing practices. The ruling reversed a permanent, worldwide injunction and, as my colleague Scott Graham wrote, provided "vindication" for the in-house lawyers who had been labelled as the "architects" of an anticompetitive licensing campaign in Koh's May 2019 order. Tom Goldstein of Goldstein & Russell handled Ninth Circuit arguments for Qualcomm's team which included lawyers from  Cravath Swaine & Moore, Keker, Van Nest & Peters, Morgan, Lewis & Bockius, and Wilson Sonsini Goodrich & Rosati.

In other big news in the patent world, a Wilmer Cutler Pickering Hale and Dorr team led by Amy Wigmore, Kevin Prussia and Bill Lee scored a huge win for clients Bristol-Myers Squibb Company and Pfizer Inc. on August 6 when U.S. District Judge Leonard Stark in Delaware found that proposed generic versions of the blockbuster drug Eliquis from three defendants in Hatch-Waxman litigation infringed patents held by their clients which don't expire until 2026 and 2031, respectively. Eliquis, a drug prescribed to reduce the risk of stroke and blood clots in people who suffer from atrial fibrillation, had $7.71 billion dollars in sales last year and ranked fourth in sales growth, according to trade publication Fierce Pharma.